TW200621804A - Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer - Google Patents

Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer

Info

Publication number
TW200621804A
TW200621804A TW094138271A TW94138271A TW200621804A TW 200621804 A TW200621804 A TW 200621804A TW 094138271 A TW094138271 A TW 094138271A TW 94138271 A TW94138271 A TW 94138271A TW 200621804 A TW200621804 A TW 200621804A
Authority
TW
Taiwan
Prior art keywords
breast cancer
antibody
aromatase inhibitor
ctla
combination treatment
Prior art date
Application number
TW094138271A
Other languages
Chinese (zh)
Inventor
Jesus Gomez-Navarro
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200621804A publication Critical patent/TW200621804A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and 10D1 (MDX-010), in combination with an aromatase inhibitor, for treatment of breast cancer. More particularly, the invention relates to administration of an anti-CTLA4 antibody and exemestane for treatment of breast cancer.
TW094138271A 2004-11-04 2005-11-01 Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer TW200621804A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62485604P 2004-11-04 2004-11-04

Publications (1)

Publication Number Publication Date
TW200621804A true TW200621804A (en) 2006-07-01

Family

ID=35825412

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094138271A TW200621804A (en) 2004-11-04 2005-11-01 Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer

Country Status (15)

Country Link
EP (1) EP1819735A1 (en)
JP (1) JP2008518902A (en)
KR (1) KR20070067702A (en)
CN (1) CN101052655A (en)
AR (1) AR053651A1 (en)
AU (1) AU2005300315A1 (en)
BR (1) BRPI0515735A2 (en)
CA (1) CA2586844A1 (en)
IL (1) IL182244A0 (en)
MX (1) MX2007003804A (en)
NO (1) NO20072576L (en)
RU (1) RU2007114111A (en)
TW (1) TW200621804A (en)
WO (1) WO2006048749A1 (en)
ZA (1) ZA200702577B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114702A2 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
BRPI0612408A2 (en) * 2005-07-07 2010-11-03 Pfizer cancer therapy in combination with anti-ctla-4 antibody and synthetic oligodeoxynucleotide containing cpg motif
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CN101909693A (en) * 2008-01-08 2010-12-08 百时美施贵宝公司 Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102227503B (en) 2008-09-26 2015-10-21 托卡根公司 Recombinant vectors
EA024877B1 (en) 2008-10-02 2016-10-31 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Cd86 antagonist multi-target binding proteins
EP2947098B1 (en) * 2009-07-20 2019-11-20 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with gemcitabine for the synergistic treatment of proliferative diseases
KR20140038382A (en) 2011-03-10 2014-03-28 프로벡투스 파마슈티컬스 인코포레이티드 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
PL2750768T3 (en) 2011-08-30 2019-05-31 Astex Pharmaceuticals Inc Decitabine derivative formulations
IL309917A (en) * 2011-10-14 2024-03-01 Genentech Inc Pertuzumab and Trastuzumab for use in therapy
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
CN103768596B (en) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 For the combination product of oncotherapy, its purposes and correlation technique
WO2014066700A1 (en) 2012-10-25 2014-05-01 Tocagen Inc. Retroviral vector with mini-promoter cassette
PT2961388T (en) 2013-03-01 2019-07-11 Astex Pharmaceuticals Inc Drug combinations
KR102338453B1 (en) * 2013-10-18 2021-12-13 리제너론 파아마슈티컬스, 인크. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
AU2016317936A1 (en) 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
CN106883298B (en) * 2015-12-16 2021-12-17 上海康岱生物医药技术股份有限公司 Bispecific conjugated antibodies, methods of making and uses thereof
CA3011009A1 (en) 2016-01-08 2017-07-13 Replimune Limited Oncolytic virus comprising a gm-csf-encoding gene and an immune co-stimulatory pathway activating molecule-encoding gene
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
TW201803905A (en) 2016-06-20 2018-02-01 克馬伯有限公司 Multispecific antibodies for immuno-oncology
CN109906088A (en) * 2016-08-26 2019-06-18 奥野哲治 Microvascular blood flow reduces agent and its application
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CA3048918C (en) 2017-03-02 2023-04-25 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
US20230113802A1 (en) * 2020-02-27 2023-04-13 University Of Washington Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies

Also Published As

Publication number Publication date
NO20072576L (en) 2007-08-03
RU2007114111A (en) 2008-12-10
BRPI0515735A2 (en) 2011-10-11
KR20070067702A (en) 2007-06-28
CA2586844A1 (en) 2006-05-11
ZA200702577B (en) 2008-07-30
CN101052655A (en) 2007-10-10
AU2005300315A1 (en) 2006-05-11
WO2006048749A1 (en) 2006-05-11
AR053651A1 (en) 2007-05-16
JP2008518902A (en) 2008-06-05
EP1819735A1 (en) 2007-08-22
MX2007003804A (en) 2007-04-23
IL182244A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
TW200621804A (en) Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer
SG163583A1 (en) Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
EA201070636A1 (en) INHIBITION OF THE PROTECTOR PROTEIN, STIMULATING MACROPHAGE (RON), AND METHODS OF ITS TREATMENT
MY166776A (en) Humanised anti-ctla4 antibodies
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
MX2012004258A (en) Inhibitors of bruton's tyrosine kinase.
TNSN05300A1 (en) Treatment with anti-vegf antibodies
UA106194C2 (en) Diagnosis and treatment of cancer using anti-ereg antibody
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
UA108193C2 (en) APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
MX2019005150A (en) Inhibitors of bruton's tyrosine kinase.
TW200736277A (en) RANKL antibody-PTH/PTHrP chimeric molecules
SG170809A1 (en) Diarylthiohydantoin compounds
BR0309254A (en) Use of an anti-ctla-4 antibody
GEP20115324B (en) Tweak binding antibodies
MX2007011545A (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors.
MXPA05011755A (en) Compositions and methods for wt1 specific immunotherapy.
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
MXPA05011922A (en) Cannabinoid receptor ligands and uses thereof.
UA85559C2 (en) Aminobenzophenone compounds
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
AU2003205768A1 (en) Methods and compositions for treating hyperproliferative conditions
WO2008013983A3 (en) Opsin stabilizing compounds and methods of use
MX337358B (en) Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof.